Robert Wharton

In this engaging discussion, Robert Wharton, a pulmonary and critical care fellow, and Nicole Ng, an Assistant Professor specialized in interstitial lung disease, dive into the FIBRONEER-IPF trial examining the new treatment, Nerandomilast, for idiopathic pulmonary fibrosis (IPF). They highlight the trial's design, enrollment criteria, and how it compares to previous studies. The duo debates the clinical implications of the trial's findings, particularly the modest FVC benefit, while addressing safety concerns and the need for better patient management strategies.

In this engaging discussion, Robert Wharton, a pulmonary fellow at Johns Hopkins, and Nicole Ng, an Assistant Professor at Mount Sinai specializing in interstitial lung disease, delve into the complexities of treating Idiopathic Pulmonary Fibrosis (IPF). They analyze the landmark INPULSIS trials and the efficacy of Nintedanib, highlighting its impact on lung function. The duo discusses challenges like participant selection in clinical trials, adverse effects of the drug, and the importance of personalized treatment strategies to improve patient outcomes.